Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Filippo de Marinis"'
Autor:
Paolo Bidoli, Daniele Turci, Hector Soto Parra, Domenico Galetta, Fabiana Vitiello, Teresa Gamucci, Paola Antonelli, Filippo de Marinis, Giuseppe Lo Russo, Angelo Delmonte, Enrico Cortesi, Francesco Grossi, Luana Calabrò, Andrea Ardizzoni, Alessandro Morabito, Diana Giannarelli, Antonio Chella, Federico Cappuzzo, Lucio Crinò, Marcello Tiseo
Publikováno v:
The Oncologist. 24:e1165-e1171
Background Nivolumab has shown a survival benefit compared with docetaxel as second-line treatment for patients with previously treated advanced squamous non-small cell lung cancer (NSCLC) in a randomized phase III trial. The experiences of patients
Autor:
Filippo de Marinis, Francesco Grossi
Publikováno v:
The Oncologist. 13:14-20
In the U.S. and Europe, the current options for the second- and third-line treatment of advanced non-small cell lung cancer (NSCLC) are cytotoxic drugs and targeted agents. Docetaxel was the first drug approved for second-line treatment after two pha
Publikováno v:
The oncologist. 12(10)
The majority of non-small cell lung cancer (NSCLC) patients present with advanced disease, and despite the improvement in efficacy and safety outcomes with platinum-based chemotherapy, this standard cytotoxic approach has reached a therapeutic platea